Early Subclinical Rejection as a Risk Factor for Late Chronic Humoral Rejection

被引:91
作者
Moreso, Francesc [1 ]
Carrera, Marta [2 ]
Goma, Montse [2 ]
Hueso, Miguel [3 ]
Sellares, Joana [3 ]
Martorell, Jaume [4 ]
Grinyo, Josep M. [3 ]
Seron, Daniel [1 ]
机构
[1] Univ Autonoma Barcelona, Hosp Univ Vall dHebron, Dept Nephrol, Barcelona 08035, Spain
[2] Hosp Univ Bellvitge, Dept Pathol, Barcelona, Spain
[3] Hosp Univ Bellvitge, Dept Nephrol, Barcelona, Spain
[4] Univ Barcelona, Dept Immunol, Hosp Clin, Barcelona, Spain
关键词
Renal transplantation; Protocol biopsies; Subclinical rejection; Transplant glomerulopathy; Interstitial fibrosis; CHRONIC ALLOGRAFT NEPHROPATHY; BASE-LINE IMMUNOSUPPRESSION; ANTIBODY-MEDIATED REJECTION; KIDNEY-TRANSPLANT PATIENTS; EARLY PROTOCOL BIOPSIES; RENAL-TRANSPLANTATION; GLOMERULOPATHY; INJURY; CLASSIFICATION; ALLOANTIBODY;
D O I
10.1097/TP.0b013e31823bb647
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Subclinical rejection and interstitial fibrosis and tubular atrophy (IF/TA) in protocol biopsies are associated with outcome. We study the relationship between histologic lesions in early protocol biopsies and histologic diagnoses in late biopsies for cause. Materials and Methods. Renal transplants with a protocol biopsy performed within the first 6 months posttransplant between 1988 and 2006 were reviewed. Biopsies were evaluated according to Banff criteria, and C4d staining was available in biopsies for cause. Results. Of the 517 renal transplants with a protocol biopsy, 109 had a subsequent biopsy for cause which showed the following histological diagnoses: chronic humoral rejection (CHR) (n = 44), IF/TA (n = 42), recurrence of the primary disease (n = 11), de novo glomerulonephritis (n = 7), T-cell-mediated rejection (n = 4), and polyoma virus nephropathy (n = 1). The proportion of retransplants (15.9% vs. 2.3%, P = 0.058) and the prevalence of subclinical rejection were higher in patients with CHR than in patients with IF/TA (52.3% vs. 28.6%, P = 0.0253). Demographic donor and recipient characteristics and clinical data at the time of protocol biopsy were not different between groups. Logistic regression analysis showed that subclinical rejection (relative risk, 2.52; 95% confidence interval, 1.1-6.3; P = 0.047) but not retransplantation (relative risk, 6.7; 95% confidence interval, 0.8 - 58.8; P = 0.085) was associated with CHR. Conclusion. Subclinical rejection in early protocol biopsies is associated with late appearance of CHR.
引用
收藏
页码:41 / 46
页数:6
相关论文
共 50 条
  • [21] Subclinical rejection impairs glomerular adaptation after renal transplantation
    Ibernon, M.
    Goma-i-Freixanet, M.
    Moreso, F.
    Fulladosa, X.
    Hueso, M.
    Cruzado, J. M.
    Torras, J.
    Bestard, O.
    Grinyo, J. M.
    Seron, D.
    KIDNEY INTERNATIONAL, 2006, 70 (03) : 557 - 561
  • [22] Development and clinical validity of a novel blood-based molecular biomarker for subclinical acute rejection following kidney transplant
    Friedewald, John J.
    Kurian, Sunil M.
    Heilman, Raymond L.
    Whisenant, Thomas C.
    Poggio, Emilio D.
    Marsh, Christopher
    Baliga, Prabhakar
    Odim, Jonah
    Brown, Merideth M.
    Ikle, David N.
    Armstrong, Brian D.
    charette, Jane I.
    Brietigam, Susan S.
    Sustento-Reodica, Nedjema
    Zhao, Lihui
    Kandpal, Manoj
    Salomon, Daniel R.
    Abecassis, Michael M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2019, 19 (01) : 98 - 109
  • [23] Impact of Subclinical Rejection on Kidney Graft Function
    Tugmen, Cem
    Sert, Ismail
    Kebapci, Eyup
    Tasli, Funda
    Karadeniz, Tugba
    Avci, Emran Kuzey
    Tuncer, Korhan
    Ayna, Tulay Kilicaslan
    Tanrisev, Mehmet
    Olmez, Mustafa
    Karaca, Cezmi
    TRANSPLANTATION PROCEEDINGS, 2019, 51 (10) : 3304 - 3308
  • [24] Rejection and function and chronic allograft dysfunction
    de Fijter, Johan W.
    KIDNEY INTERNATIONAL, 2010, 78 : S38 - S41
  • [25] The role of mesenchymal stromal cells in chronic transplant rejection after solid organ transplantation
    Reinders, Marlies E. J.
    Rabelink, Ton J.
    de Fijter, Johan W.
    CURRENT OPINION IN ORGAN TRANSPLANTATION, 2013, 18 (01) : 44 - 50
  • [26] Effects of antirejection therapies for early subclinical acute rejection in renal transplant protocol biopsies
    Sakurabayashi, Kei
    Muramatsu, Masaki
    Itabashi, Yoshihiro
    Oguchi, Hideyo
    Kawamura, Takeshi
    Hamasaki, Yuko
    Mikami, Tetsuo
    Tochigi, Naobumi
    Shishido, Seiichiro
    Sakai, Ken
    RENAL REPLACEMENT THERAPY, 2022, 8 (01)
  • [27] Effects of antirejection therapies for early subclinical acute rejection in renal transplant protocol biopsies
    Kei Sakurabayashi
    Masaki Muramatsu
    Yoshihiro Itabashi
    Hideyo Oguchi
    Takeshi Kawamura
    Yuko Hamasaki
    Tetsuo Mikami
    Naobumi Tochigi
    Seiichiro Shishido
    Ken Sakai
    Renal Replacement Therapy, 8
  • [28] Early and late antibody mediated rejection: Which game is the complement playing?
    Marco, Delsante
    Ilaria, Gandolfini
    Alessandra, Palmisano
    Benigno, Giuseppe Daniele
    Micaela, Gentile
    Rossi, Giovanni Maria
    Enrico, Fiaccadori
    Umberto, Maggiore
    TRANSPLANTATION REVIEWS, 2025, 39 (01)
  • [29] Tocilizumab in the treatment of active chronic humoral rejection resistant to standard therapy
    Chamouna, Betty
    Sanchez-Sancho, Pablo
    Torres, Irina B.
    Gabaldon, Alejandra
    Perello, Manel
    Sellares, Joana
    Moreso, Francesc
    Serona, Daniel
    NEFROLOGIA, 2022, 42 (05): : 578 - 584
  • [30] Increase in spot urine protein excretion is associated with late kidney graft rejection and predicts rejection phenotype
    Arnol, Miha
    Oblak, Manca
    Mlinsek, Gregor
    Lindic, Jelka
    Kandus, Aljosa
    Ferluga, Dusan
    Kojc, Nika
    Buturovic-Ponikvar, Jadranka
    CLINICAL NEPHROLOGY, 2017, 88 : S83 - S90